The Drugs (Thirteenth Amendment) Rules, 2026, which amend Rule 31 of the Drugs Rules, 1945, came into force on 28 October 2026. A drug cannot now be imported with less than 12 months of residual shelf life on the date of import.
The new floor replaces the old rule, under which more than 60% of a drug's approved shelf life had to remain at import.
Biological drugs and radiopharmaceuticals keep a percentage test: 60% of their labelled shelf life must remain.
The draft was published for comment on 22 June 2026. The final rules followed consultation with the Drugs Technical Advisory Board (DTAB).
| Approved shelf life | Old rule (>60% left) | New rule (12 months left) | Effect |
|---|---|---|---|
| 18 months | About 11 months | 12 months | Slightly stricter |
| 20 months | 12 months | 12 months | Same: the break-even point |
| 24 months | About 15 months | 12 months | Looser |
| 36 months | About 22 months | 12 months | Much looser |
The parent Act. Section 10 prohibits the import of certain drugs, and Section 5 constitutes the DTAB.
The import rule amended here, swapping the 60% residual shelf-life test for a 12-month floor. Cosmetics now fall under the separate Cosmetics Rules, 2020.
The amending rules, in force from 28 October 2026.
Statutory body under Section 5 of the Drugs and Cosmetics Act, 1940, advising governments on technical matters; consulted on this amendment
National drug regulator and licensing authority for drug imports
Notified the amendment
GS Paper 2 > Health; statutory and regulatory bodies; GS Paper 3 > Pharmaceutical sector
General Awareness > Government rules and regulations
General Awareness > Pharma and trade policy
The time left before a product's expiry date on a given day; here, the date of import
Date until which the manufacturer guarantees a drug's full potency and safety
Medicine made from, extracted from or semi-synthesised from biological sources, such as vaccines and monoclonal antibodies
Drug containing a radioactive isotope, used in diagnosis or therapy